https://orcid.org/0000-0002-6671-0115
References
- Vyse A, Campling J, Czudek C, et al. A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK. Expert Rev Vaccines. 2021;20:1311–1325.
- Lawrence H, Pick H, Baskaran V, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: a case-control test-negative design study. PLOS Med. 2020;17:e1003326.
- Bonten M, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114–1125.
- Treskova M, Scholz S, Kuhlmann A. Cost effectiveness of elderly pneumococcal vaccination in Presence of higher-valent pneumococcal conjugate childhood vaccination: systematic literature review with focus on methods and assumptions. PharmacoEconomics. 2019;37:1093–1127.
- Kawakami K, Kishino H, Kanazu S, et al. Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly. Hum Vaccin Immunother. 2018;14:1931–1938.
- Paradiso PR. Pneumococcal conjugate vaccine for adults: a new paradigm. Clin Infect Dis. 2012;55:259–264.
- Falkenhorst G, Remschmidt C, Harder T, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One. 2017;12:e0169368.
- Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1:CD000422.
- Berild J, Winje B, Vestrheim D, et al. A systematic review of studies published between 2016 and 2019 on the effectiveness and efficacy of pneumococcal vaccination on pneumonia and invasive pneumococcal disease in an elderly population. Pathogens. 2020;9:259.
- Winje B, Berild J, Vestrheim D, et al. Efficacy and effectiveness of pneumococcal vaccination in adults – an update of the literature. 978-82-8406-053-8. Published by the Norwegian Institute of Public Health, Oslo, Norway. December 2019. The report can be downloaded as pdf at www.fhi.no/en/publ
- Djennad A, Ramsay ME, Pebody R, et al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales. EClinicalMedicine. 2018;6:42–50.
- Ladhani S, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18:441–451.
- Pick H, Daniel P, Rodrigo C, et al. Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013–18. Thorax. 2020;75(1):38–49.
- Ramirez J, Wiemken T, Peyrani P, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65:1806–1812.
- Rai Y, Tessier E, Roy P. Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2020 to March 2021 health protection report volume 15 number 19.